Penumbra Shares Are Trading Higher After the Company Announced It Completed the Enrollment in Its THUNDER Clinical Study for Patients With Acute Ischemic Stroke. Also, Truist Securities Maintained a Buy Rating on the Stock and Raised Its Price Target...

Penumbra股票正在交易上漲，因公司宣佈已完成急性缺血性中風患者的THUNDER臨床研究招募。此外，Truist證券維持了對該股票的買入評級，並提高了其價格目標...

Benzinga · 10/14 23:29

Penumbra Shares Are Trading Higher After the Company Announced It Completed the Enrollment in Its THUNDER Clinical Study for Patients With Acute Ischemic Stroke. Also, Truist Securities Maintained a Buy Rating on the Stock and Raised Its Price Target From $200 to $235.

Penumbra股票交易價格上漲，因公司宣佈完成了其THUNDER臨床研究的患者急性缺血性中風的招募。此外，Truist Securities維持了對該股的買入評級，並將其目標股價從200美元上調至235美元。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。